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Abstract 
 
RIP140 is a ligand-dependent corepressor for most, if not all nuclear receptors.  It is 
expressed widely in many different tissues, but the phenotype of mice devoid of 
RIP140 indicates that it plays a crucial role in the ovary and in adipose biology.  
Ovarian expression of RIP140 is cell type-specific during follicular development and 
it is essential for oocyte release during ovulation, but not for luteinisation of mature 
ovarian follicles.  In adipose tissue, RIP140 is essential for normal fat accumulation 
and RIP140 null mice show decreased lipid storage even on a high fat diet, with 
upregulation of mitochondrial uncoupling protein (UCP1) in some fat depots. Thus 
RIP140 plays a crucial role in female fertility and in energy homeostasis, and could be 






Nuclear receptors control a vast array of endocrine responses by controlling the 
activity of specific subsets of target genes in cells, usually for precise periods of time.  
Their ability to regulate gene transcription depends on the recruitment of coactivators 
and corepressors that remodel chromatin in the vicinity of their promoters. Numerous 
coactivators have been reported but the p160/SRC (steroid receptor coactivator) 
family of coactivators and CBP/p300 seem to play an important role in transcriptional 
activation by many members of the nuclear receptor family (McKenna & O'Malley, 
2002).  NCoR (nuclear receptor corepressor) and SMRT (silencing mediator for 
retinoic acid receptor and thyroid hormone receptor) (Jepsen et al., 2000, Nagy et al., 
1997) were the first corepressors to be identified and found to block the 
transcriptional activity of a subset of nuclear receptors.  RIP140 is a corepressor that 
binds to most, if not all, nuclear receptors (Cavailles et al., 1995, L'Horset et al., 
1996) and its importance in endocrine responses is evident from the observation that it 
is essential for female fertility (Leonardsson et al., 2002, White et al., 2000) and 
energy homeostasis (Leonardsson et al., 2004). This review will focus on the function 
of RIP140 in the ovary to regulate ovulation and in adipose tissue to regulate fat 
accumulation.  
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 RIP140 binds to nuclear receptors in a ligand-dependent manner by a 
mechanism which resembles that of the p160 coactivators.   These cofactors contain 
helical leucine-rich LXXLL motifs that dock into a cleft formed by the activation 
surface in the ligand binding domain of nuclear receptors when a hormonal ligand is 
bound (Heery et al., 1997) (Torchia et al., 1997).  The mechanisms that determine 
whether, for example a p160 coactivator or the RIP140 corepressor is recruited to a 
particular nuclear receptor and precisely when and for how long are not known but 
there are hints that several mechanisms may be involved.  These include variations in 
their relative cellular concentrations, alterations in their subcellular location in 
response to other signalling pathways and regulation of their activity brought about 
post-translational modifications. The binding properties of NCoR and SMRT are quite 
distinct from these cofactors since they contain extended LXXLL-like motifs (Hu & 
Lazar, 1999) that can not fit into the cleft formed on activated receptors but bind to 
certain nuclear receptors, including retinoic acid and thyroid hormone receptors, in 
the absence of hormone and to steroid receptors in the presence of antagonists (Huang 
et al., 2002, Liu et al., 2002, Shang & Brown, 2002).  Despite differences in the 
binding properties of cofactors to nuclear receptors they all seem to act as docking or 
scaffold proteins for the assembly of enzyme complexes at specific sites on a 
promoter.  The function of these enzymes, which include acetylases/deacetylases, 
kinases/phosphatases and methyl transferases, is to catalyse the modification of 
histones, that results in the remodelling of chromatin and ultimately gene activation or 
gene repression.     
 
 A schematic diagram of the structure of RIP140 is shown in Figure 1.  It 
consists of ten leucine-rich motifs that allow its recruitment to the ligand binding 
domain of nuclear receptors (Heery et al., 1997) (Torchia et al., 1997) and four 
repression domains (Christian et al., 2004).  Individual LXXLL motifs are assumed to 
allow selective binding to different receptors; for example motif 10, LXXML, is 
reported to bind preferentially to retinoid receptors (Lee & Wei, 1999).  The 
repression domains exhibit autonomous activity suggesting that they function by 
recruiting enzymes that modify histones or DNA.  Repression domain 1 has been 
found to bind histone deacetylases (HDACs) (Wei et al., 2000) while repression 
domain 2 binds carboxy-terminal binding protein (CtBP) that then bind enzymes, 
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including histone deacetylases (Vo et al., 2001).  The mechanism of action of 
repression domains 3 and 4 are unknown (Christian et al., 2004).  Nevertheless it 
seems likely that the four repression domains allow the regulated recruitment of 
distinct sets of chromatin modifying enzymes each of which is capable of repressing 
transcription from target genes. 
  
 RIP140 is detected in most tissues but only in specific cell types where its 
expression is often under developmental or hormonal control.  This is achieved by the 
presence of multiple promoters that precede a number of alternately spliced 
untranslated exons which are differentially regulated (Donna Nichol, unpublished 
data). The biological roles of RIP140 have been determined by generating mice 
devoid of the gene.  The coding sequence of the RIP140 gene was replaced by lacZ to 
allow for the detection of β−galactosidase at sites at which the RIP140 promoter is 
active (White et al., 2000).  The highest levels of RIP140 expression are in the gonads 
and in metabolic tissues, particularly adipose tissue, where it clearly plays important 
roles.  While RIP140 is not required for viability it is essential for female fertility 
since it plays a crucial role in oocyte release by the ovary during ovulation 
(Leonardsson et al., 2002).  It is important for fat accumulation in white adipose 
tissue so that in its absence mice are extremely lean (Leonardsson et al., 2004).  It 
also plays a role in growth and probably has many other functions in view of its 
widespread expression in tissues, but these are yet to be determined.    
 
 
Role of RIP140 in Female Reproduction. 
 
Female mice devoid of RIP140 (RIPKO mice) are completely infertile because they 
fail to ovulate.  Thus RIPKO mice fail to release oocytes from mature follicles 
following the pre-ovulatory surge of luteinising hormone (LH), (Figure 2 A,B), 
although luteinisation still occurs (White et al., 2000). This phenotype closely 
resembles that of luteinised unruptured follicle syndrome often associated with 
infertility in women, and suggests that  suppression of nuclear receptors is essential 
for the normal coordinated control of ovarian function, with the process of oocyte 
release dependent on the activity of RIP140. 
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Further investigation of the ovarian phenotype demonstrated that ovulatory failure is 
due to a primary defect in the ovary itself.  Standard hormone treatments (PMSG and 
hCG) designed to “superovulate” mice had no effect on oocyte release (White et al., 
2000), indicating that the defect is independent of gonadotrophin stimulation of 
follicle growth or the LH surge.  In addition ovarian transplantation experiments gave 
direct evidence that the defect lies at the ovarian level rather than the hypothalamic-
pituitary axis (Leonardsson et al., 2002).  Ovaries from 4-week old immature RIPKO 
mice were transferred into wild-type or heterozygous littermates and vice-versa.  
Continuous breeding experiments indicated that the transfer of ovaries from wild-type 
into RIPKO mice rescued their fertility whereas control mice with RIP140 null 
ovaries generated very few pups, all of which were dead at birth or died within 72 
hours.  The conclusion was that RIP140 expression in the ovary is necessary for 
ovulation and that expression in other tissues is not essential for this process to occur.  
 
The precise site of RIP140 action in the ovary required for ovulation has not been 
determined definitively. RIP140 expression, as determined by analysing β-
galactosidase activity as a marker of promoter activity (Figure 2), indicated that the 
highest levels are found in granulosa cells but low levels are also present in thecal and 
interstitial cells.  No expression was detected in the granulosa cells of primary 
follicles or small follicles, but expression increased during follicular maturation, with 
the highest level detected in the outer mural cells in pre-ovulatory follicles (Figure 
2C). Expression levels dramatically decreased after luteinisation but were 
subsequently regulated in the corpora lutea of pregnant mice (Figure 2D-G).  In 
ovaries of heterozygous or RIPKO mice used for embryo transfer there is negligible 
expression from the RIP140 promoter in corpora lutea at day 6.5 post-coitus (p.c.), 
but expression increases at mid-gestation, is maintained until at least day 13.5 p.c., 
and then declines to negligible levels at day 17.5 p.c., correlating with initiation of the 
regression of the corpora lutea.  While initial failure of oocyte release did not affect 
luteinization and production of progesterone in the early stages of pregnancy, the 
normal mid-gestation rise in progesterone levels was not as pronounced in embryo-
transferred RIP140 null mice.  This is despite the fact that the corpora lutea were still 
large and apparently healthy (Leonardsson et al., 2002). 
  6 
 
RIP140 may also play a role in uterine function given that it is in the glandular 
epithelium, stroma and myometrium of the non-pregnant uterus (Figure 2H).  To 
investigate its function during pregnancy embryo transfer experiments were 
performed.  The transfer of wild-type embryos into pseudopregnant RIPKO females 
resulted in a similar number of implantation sites as wild-type mice, indicating that 
uterine RIP140 is not required for implantation.  Nevertheless RIP140 was expressed 
in primary decidual cells around the time of implantation and, by 9.5 days p.c., in 
differentiating decidual cells on the anti-mesometrial side of the uterus (Leonardsson 
et al., 2002). At later stages of pregnancy, however, there was a progressive reduction 
in the number of surviving embryos in the RIP140 null mice suggesting that uterine 
RIP140 expression might be required to maintain the pregnancy.  In addition, while 
the majority of pups born from control mothers survived after birth, 75% of the pups 
from RIP 140 null mothers were dead within 24 hours (Leonardsson et al., 2002). 
  
The high incidence of fetal loss in mid-pregnancy and the death of the majority of 
pups at or shortly after birth following embryo transfer suggests that some aspects of 
the maternal expression of RIP140 are sub-optimal for the maintenance of pregnancy 
and for the subsequent survival of offspring. However, the ovarian transfer 
experiments indicated that uterine and mammary gland RIP140 expression is not 
essential for pregnancy and survival. We conclude from this apparent disparity that 
the pregnancy failure and the death of pups may reflect a defect in the RIP 140 null 
ovary which fails to support fully the function of the uterus and the mammary gland.  
 
 
Role of RIP140 in Adipose Tissue. 
 
The defects in fertility are accompanied by metabolic changes in the RIP140 null 
mice, which are lean with a 20% reduction in body weight in both males and females 
compared to wild type mice. Magnetic resonance imaging (MRI) and spectroscopy 
(MRS) of whole body fat content revealed marked decrease in subcutaneous fat and 
other fat depots (Leonardsson et al., 2004).  Total body fat content was reduced by 
approximately 70% as analysed by whole body proton MRS while the weight of 
inguinal white adipose tissue (WAT) was reduced by 40-60%, according to the age of 
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the mice. The reduction in body weight and fat content was not due to increased 
physical activity, although RIPKO mice showed increased oxygen consumption.  In 
addition, food intake was 4.93 ± 0.37 g/mouse/day and 4.70 ± 0.20 g/mouse/day in 
wild type and null mice respectively, corresponding to a small increase in the null 
mice relative to total body weight (Leonardsson et al., 2004).  
 
Further investigation showed that the RIP140 null mice are lean because they fail to 
store triglycerides and are resistant to high-fat diet induced obesity, suggesting that 
alternative mechanisms are involved in the dissipation of excess fuel (Leonardsson et 
al., 2004).  The most striking finding was the upregulation, by more than 100 fold, of 
mitochondrial uncoupling protein 1 (UCP1) mRNA, in inguinal WAT of RIPKO 
mice.   In RIPKO mice fed on a normal diet, adipocyte volume was 2.7 fold less in 
inguinal WAT, compared to wild type littermates, while there were no differences in 
the adipocytes in the interscapular brown adipose tissue (BAT) and there was no 
evidence from Oil red O staining or MRI/MRS that fat was being stored in alternate 
tissues such as the liver.   In animals fed on a high fat diet, RIPKO mice gained less 
weight than wild type mice and showed a smaller increase in adipocyte volume.  
Lipid accumulation in the liver on high fat diet was seen in wild type but not in 
RIPKO mice, showing that the absence of RIP140 protects against hepatic steatosis 
(Leonardsson et al., 2004).  
 
White and brown adipose tissue can be distinguished by the morphology of the 
adipocytes; unilocular white adipocytes store energy as triglycerides and release it 
when required, whereas multilocular brown adipocytes dissipate energy as heat.  
White and brown adipocytes are distributed in different proportions in distinct fat 
depots in mice, and the depots can be classified as subcutaneous or visceral in origin 
(Figure 3A).  In mature animals, most of the BAT is found in the interscapular depot, 
but in young animals it can also be found in the posterior subcutaneous (dorsolumbar, 
inguinal and gluteal) and mediastinic and perirenal depots, mainly composed of 
WAT.   Visceral WAT depots include mesenteric and gonadal, epididymal or ovarian, 
fat (Cinti, 2002). 
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The dramatic increase in UCP1 expression in the subcutaneous inguinal fat depot in 
RIPKO mice was accompanied by a change in the balance between unilocular and 
multilocular adipocytes, as shown by histology and immunohistochemistry for UCP1 
(Leonardsson et al., 2004).   The different fat depots in RIPKO and wild type mice 
were compared.  In inguinal fat, regarded as a typical subcutaneous WAT depot, 
UCP1-immunoreactive multilocular and unilocular cells were present in RIPKO mice 
but not in their wild type littermates (Figure 4 A,B).  In unilocular adipocytes of 
RIPKO, the UCP1 immunoreactivity was localised mainly in the perinuclear area, 
similar to expression seen in mice expressing an aP2-Ucp1 transgene (Rossmeisl et 
al., 2002) (Figure 4B).   Interscapular brown fat, regarded as a typical BAT depot, 
was similar in wild type and RIPKO mice (Figure 4 C,D) and the peri-renal fat was 
composed of similar amounts of brown and white adipocytes in both genotypes 
(Figure 4 E,F).  In contrast to the inguinal fat, visceral WAT depots such as 
epididymal and ovarian WAT did not appear to contain multilocular cells or UCP1-
immunoreactive cells in RIPKO mice (Figure 4 G,H).  This suggests that RIP140 
plays a more important role in subcutaneous than in visceral depots in mice.  It is now 
clear that the adipocyte itself may act as an endocrine cell such that altered adipocyte 
function cause changes in systemic energy balance (Spiegelman & Flier, 2001), 
therefore regulation of lipid storage and metabolism by adipocytes in different fat 
depots is increasingly seen as an important mechanism for controlling energy balance 
in humans and may be involved in other physiological processes. 
 
There is evidence of nuclear receptor action in adipose tissue in humans, because 
estrogen (acting through ERα) controls fat accumulation in subcutaneous rather than 
visceral adipose tissue in females by upregulating α2A-adrenergic receptors 
(Pedersen et al., 2004).   Such depot-specific expression of key genes involved in fat 
deposition and mobilisation may also be mediated by peroxisome proliferator-
activated receptor-γ (PPAR-γ), since  PPAR-γ agonists, used to treat insulin 
resistance, exert depot-specific effects upon human fat deposition (Laplante et al., 
2003).   In rats, leptin mRNA levels are higher in gonadal and retroperitoneal (intra-
abdominal depots) than in inguinal (subcutaneous) adipose tissues (Zheng et al., 
1996), while glucocorticoid receptor expression is higher in epididymal than inguinal 
and retroperitoneal depots (Zhang et al., 2002).  Angiotensinogen expression changes 
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on high-fat feeding in visceral fat depots in mice, but not in subcutaneous depots nor 
in brown adipose tissue (Rahmouni et al., 2004).   The differential regulation of 
adipocyte function between subcutaneous and visceral depots in humans is an 
important area for investigation because increased visceral adipose tissue in human 
obesity is associated with pathological effects such as hypertension and metabolic 
syndrome, whereas subcutaneous fat deposition is less harmful. 
 
 
Other Sites of RIP140 Action 
 
RIP140 is widely expressed and so it is likely that the corepressor may play a role in 
other tissues, apart from the obvious phenotypes seen in reproductive system and 
adipose tissue. Real-time TaqMan PCR showed the highest levels of  RIP140 mRNA 
in WAT, followed by skeletal muscle, with lower levels in BAT and liver (Figure 
3B). 
 
Expression of RIP140, as revealed by detection of β-galactosidase by histochemical 
staining, showed that the gene is expressed in specific cells in a variety of other 
tissues, mainly in hormone-responsive cell types.   In the salivary gland the gene is 
expressed in ducts of the sublingual gland and in granular convoluted tubules (GCT) 
of the submandibular gland (Figure 5A,B). The differentiation and maintenance of 
GCT cells are under the control of the synergistic actions of androgens, thyroid 
hormones and adrenocortical hormones (Kim et al., 2001), suggesting that nuclear 
receptor cofactors have a role to play in these cells.   In the kidney RIP140 is 
expressed in a variety of epithelial cells, in proximal and distal convoluted tubules, 
the loop of Henle and collecting ducts (Figure 5C,D).  In male mice, RIP140 is 
expressed in epididymal epithelial cells, in the prostate and the testis.  In addition, β-
galactosidase staining is present in blood vessels and neuronal ganglia in a variety of 
tissues. 
 
RIP140 is present in neurones in many different brain regions, such as the cerebral 
cortex, cerebellum (Figure 5E,F) and hippocampus.  It is also expressed in anterior 
and intermediate lobes of the pituitary gland but not in the posterior lobe (Figure 5G), 
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and in sections of RIPKO mouse pituitary, anterior pituitary cells immunoreactive for 
different pituitary hormones (ACTH, GH, PRL, TSHβ, LHβ, FSHβ) all expressed β-
galactosidase.  However, comparison of immunostained pituitary sections from wild 
type and RIPKO mice showed no apparent differences in the distribution of cells 
producing these trophic hormones, suggesting that although RIP140 is expressed in 





The phenotype of RIP140 null mice shows that RIP140 plays a crucial role in 
reproduction and in energy homeostasis and demonstrates a crucial role for the 
corepressor in ovarian and adipocyte function.    Since RIP140 is recruited to nuclear 
receptors in a ligand-dependent process, it appears that it is required to prevent the 
expression of genes that might otherwise disrupt the normal biological function of 
these tissues.  Thus, one important role for RIP140 in white adipose tissue may be to 
prevent UCP1 expression.  However, the absence of RIP140 in adipose tissue not only 
allows increased expression of certain genes, but also causes decreased expression of 
other genes such as acetyl CoA carboxylase 1 (ACC-1), fatty acid synthase (FAS) and 
stearoyl CoA desaturase (SCD-1) (Leonardsson et al., 2004).  This might reflect the 
ability of  the RIP140 corepressor to block transrepression, reported in the case of 
glucocorticoids (Subramaniam et al., 1999), so that the expression of such target 
genes would increase in cells lacking the corepressor.  Alternatively, the expression of 
these genes may be subject to regulatory mechanisms, not only intrinsic to the 
adipocyte, but also to systemic factors that might be disrupted by the lack of RIP140 
in distinct endocrine tissues. 
 
RIP140 may therefore provide a novel therapeutic target for the treatment of obesity 
and related disorders. Further investigation of the role of this corepressor in ovulation 
may bring about new opportunities for treating infertility or the development of new 
contraceptive strategies. 
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Figure legends 
 
Figure 1:  Schematic representation of the RIP140 protein showing repression 
domains (RD1-RD4) and leucine motifs (numbered 1-10). 
 
Figure 2: Ovarian phenotype:  
Sections of wild type (A) and RIP140 null (RIPKO) (B) ovary stained with 
haematoxylin and eosin, showing retained oocytes (arrows) in corpora lutea.  
(C) β-galactosidase staining in specific cell types in RIPKO ovarian follicle;  
and in ovaries from non-pregnant (D) and pregnant (E-G) RIPKO mice, showing 
corpora lutea at 6.5, 10.5, and 17.5 days p.c.  CL, corpus luteum, TC, thecal cells; 
GCm, mural granulosa cells; GCc, cumulus granulosa cells; O, oocyte. 
(Η) β-galactosidase staining in RIPKO uterus, mainly in stroma and glandular 
epithelium. S, stroma; LC, luminal epithelium; GE, glandular epithelium. 
 
Figure 3: (A) Diagram of distribution of fat depots in the mouse (after Cinti, 2002); 
inguinal fat was used as typical depot for white adipose tissue (WAT) and 
interscapular fat as a typical depot for brown adipose tissue (BAT).  (B) Histogram 
showing relative levels of RIP140 mRNA in different tissues; WAT, white adipose 
tissue; BAT, brown adipose tissue; Mu, skeletal muscle; Li, liver. 
 
Figure 4:  Immunocytochemistry for UCP1 in different fat depots in wild type 
(A,C,E,G) and RIPKO (B,D,F,H ) mice (Chemicon antibody AB3038, avidin-biotin 
peroxidase method). (A,B) subcutaneous inguinal WAT,  (C,D) interscapular BAT, 
(E,F) peri-renal WAT and BAT, (G,H) epididymal WAT. 
 
Figure 5. β-galactosidase (blue) staining in various tissues in RIPKO mice showing 
cells normally expressing RIP140, nuclei counterstained with Nuclear Fast Red.  
Labelling is found in ducts in the sublingual salivary gland (A) and in granular 
convoluted tubules in submandibular (B) salivary gland.  Labelling was also found in 
proximal (PCT) and distal (DCT) convoluted tubules in the renal cortex, but not in 
glomeruli (C), and in collecting tubules in the renal medulla (D).  Labelling was also 
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found in the cerebral cortex (E), cerebellum (F) and in the pituitary gland (G); a, 
anterior lobe; i, intermediate lobe; p, posterior lobe. 
 
 
 
 
